<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32221024</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>17</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e1835</StartPage><EndPage>e1844</EndPage><MedlinePgn>e1835-e1844</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000009322</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine whether lipids and apolipoproteins predict prognosis of patients with amyotrophic lateral sclerosis in a cohort study of 99 patients with amyotrophic lateral sclerosis who were diagnosed during 2015 to 2018 and followed up until October 31, 2018, at the Neurology Clinic in Karolinska University Hospital in Stockholm, Sweden.</AbstractText><AbstractText Label="METHODS">Total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein AI, apolipoprotein B, and lipid ratios were measured at the time of amyotrophic lateral sclerosis diagnosis or shortly thereafter. Death after amyotrophic lateral sclerosis diagnosis was used as the main outcome. The Cox model was used to estimate hazard ratios with 95% confidence intervals of death after amyotrophic lateral sclerosis diagnosis, after controlling for sex, age at diagnosis, site of symptom onset, diagnostic delay, body mass index, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised score, and progression rate.</AbstractText><AbstractText Label="RESULTS">A 1-SD increase of total cholesterol (hazard ratio 0.60, 95% confidence interval 0.41-0.89, <i>p</i> = 0.01), low-density lipoprotein cholesterol (hazard ratio 0.64, 95% confidence interval 0.44-0.92, <i>p</i> = 0.02), low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio (hazard ratio 0.65, 95% confidence interval 0.46-0.92, <i>p</i> = 0.02), apolipoprotein B (hazard ratio 0.62, 95% confidence interval 0.44-0.88, <i>p</i> = 0.01), or apolipoprotein B/apolipoprotein AI ratio (hazard ratio 0.61, 95% confidence interval 0.43-0.86, <i>p</i> &lt; 0.01) was associated with a lower risk of death after amyotrophic lateral sclerosis diagnosis. A dose-response relationship was also noted when these biomarkers were analyzed as categorical variables.</AbstractText><AbstractText Label="CONCLUSIONS">Lipids and apolipoproteins are important prognostic indicators for amyotrophic lateral sclerosis and should be monitored at the diagnosis of amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Yiqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Termorshuizen</LastName><ForeName>Jet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3310-6456</Identifier><AffiliationInfo><Affiliation>From the Department of Clinical Neuroscience (C.I.), and Department of Medical Epidemiology and Biostatistics (L.C., Y.Z., J.T., L.Y., F.F.), Karolinska Institutet; and Neurology Clinic (C.I.), Karolinska University Hospital, Stockholm, Sweden. fang.fang@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001053">Apolipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001053" MajorTopicYN="N">Apolipoproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32221024</ArticleId><ArticleId IdType="pmc">PMC7274849</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000009322</ArticleId><ArticleId IdType="pii">WNL.0000000000009322</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc Med 2014;107:14&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883149</ArticleId><ArticleId IdType="pubmed">24399773</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Hardiman O, Benatar M, et al. . Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12:310&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, et al. . Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011;10:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstrom H, et al. . Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol 2017;81:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yazdani S, Piehl F, et al. . Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging 2018;67:202 e1&#x2013;02 e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a mendelian randomization study. Hum Mol Genet 2019;28:688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, et al. . Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 2019;85:470&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C. Smoking is a cause of ALS: high LDL-cholesterol levels? Unsure. Ann Neurol Epub 2019 Mar 18.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883903</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, et al. . Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008;70:1004&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Ilardi A, et al. . Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology 2009;73:1681&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Kuhnlein P, Hendrich C, et al. . Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011;258:613&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128082</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, et al. . Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011;82:638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Bovio G, et al. . Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 2014;71:1134&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, et al. . Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Deng J, Jaffa M, et al. . Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 2011;44:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441750</ArticleId><ArticleId IdType="pubmed">21607987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, et al. . Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med 2012;51:1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic SI, Stevic Z, Dedic V, et al. . Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol Res 2012;34:576&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">22732100</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Acimovic J, Lovgren-Sandblom A, et al. . Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS: evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS One 2014;9:e113619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Guo X, Chen X, et al. . The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Rosi E, Fini N, et al. . Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci 2017;38:2177&#x2013;2182.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Highton-Williamson E, Caga J, et al. . Lipid metabolism and survival across the frontotemporal dementia-amyotrophic lateral sclerosis spectrum: relationships to eating behavior and cognition. J Alzheimers Dis 2018;61:773&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">29254092</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros A, Dourado MET Jr, Pedrosa LFC, et al. . Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis. J Nutr Metab 2018;2018:5678698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6079445</ArticleId><ArticleId IdType="pubmed">30116640</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Regodon Wallin A, Samuelsson K, et al. . The Swedish motor neuron disease quality registry. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">30296856</ArticleId></ArticleIdList></Reference><Reference><Citation>Millan J, Pinto X, Munoz A, et al. . Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009;5:757&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747394</ArticleId><ArticleId IdType="pubmed">19774217</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486&#x2013;2497.</Citation><ArticleIdList><ArticleId IdType="pubmed">11368702</ArticleId></ArticleIdList></Reference><Reference><Citation>Walldius G, Jungner I, Holme I, et al. . High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755609</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Brayne C, et al. . The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry 2017;88:557&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pubmed">28285264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez De Aguilar JL. Lipid biomarkers for amyotrophic lateral sclerosis. Front Neurol 2019;10:284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott DA, Weickert CS, Garner B. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol 2010;51:555&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058497</ArticleId><ArticleId IdType="pubmed">21423873</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>